Liu Jingxin, Zhao Cai, Chen Jiahao, Zeng Pengguihang, Li Qingjian, Dai Ranran, Lai Xingqiang, Song Wenqian, Chen Jianing, Zhu Xixi, Liu Xinyi, Sun Jun, Wang Jia, Fang Peihang, Wang Tengfei, Chen Wenjie, Guallar Diana, Cao Nan, Zhao Jianli, Su Shicheng, Xiang Andy Peng, Zeng Yi Arial, Li Jie, Cai Junchao, Lee Dung-Fang, Bei Jinxin, Huo Yongliang, Hu Hai, Suo Shengbao, Huang Dong-Feng, Bai Jin, Ding Junjun
Department of Rehabilitation Medicine, The Seventh Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Shenzhen, Guangdong, 518107, China.
Cancer Institute, Xuzhou Medical University, 221002, Jiangsu, China.
Sci Adv. 2025 Jul 25;11(30):eadi2370. doi: 10.1126/sciadv.adi2370.
Breast cancer is the most common malignancy in females and remains the leading cause of cancer-related deaths for women worldwide. The cellular and molecular basis of breast tumorigenesis is not completely understood partly due to the lack of human research models which simulate the development of breast cancer. Here, we developed a method for generating functional mammary-like cells (MCs) from human-induced pluripotent stem cells (iPSCs). The iPSC-MCs closely resemble human primary MCs at cellular, transcriptional, and functional levels. Using this method, a breast cancer model was generated using patient-derived iPSCs harboring germline mutation. The patient iPSC-MCs recapitulated the transcriptome, clinical genomic alteration, and tumorigenic ability of breast cancer cells. We also identified S100P as an oncogene downstream of mutated that promotes cancer cell stemness and tumorigenesis. Our study establishes a promising system of breast cancer for studying the mechanism of tumorigenesis and identifying potential therapeutic targets.
乳腺癌是女性中最常见的恶性肿瘤,并且仍然是全球女性癌症相关死亡的主要原因。由于缺乏模拟乳腺癌发展的人类研究模型,乳腺癌发生的细胞和分子基础尚未完全明确。在此,我们开发了一种从人诱导多能干细胞(iPSC)生成功能性乳腺样细胞(MC)的方法。iPSC-MC在细胞、转录和功能水平上与人类原代MC非常相似。使用这种方法,利用携带种系突变的患者来源的iPSC生成了一个乳腺癌模型。患者iPSC-MC概括了乳腺癌细胞的转录组、临床基因组改变和致瘤能力。我们还确定S100P是突变下游的一种癌基因,可促进癌细胞干性和肿瘤发生。我们的研究建立了一个有前景的乳腺癌系统,用于研究肿瘤发生机制和识别潜在的治疗靶点。